莲花健康(600186) - 2023 Q1 - 季度财报
LHGLHG(SH:600186)2023-04-28 16:00

Financial Performance - The company's operating revenue for Q1 2023 was ¥455,779,558.55, representing a year-on-year increase of 9.18%[5] - The net profit attributable to shareholders was ¥20,987,154.16, reflecting a significant increase of 43.23% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.0117, which is an increase of 46.25% year-on-year[5] - In Q1 2023, the company reported a net profit of CNY 22,037,147.18, an increase of 40.5% compared to CNY 15,668,519.37 in Q1 2022[21] - The total revenue from operating activities was CNY 517,496,855.77, up from CNY 487,993,984.20 in the same period last year, reflecting a growth of 6.5%[24] - The company's operating profit reached CNY 28,440,895.40, representing a 33.5% increase from CNY 21,374,494.15 in the previous year[21] - The total comprehensive income for Q1 2023 was CNY 22,037,147.18, compared to CNY 15,665,631.69 in Q1 2022, reflecting a growth of 40.5%[22] Cash Flow and Assets - The net cash flow from operating activities decreased by 63.59%, amounting to ¥21,583,761.97[5] - The company's cash and cash equivalents as of March 31, 2023, amounted to RMB 1,352,872,179.09, slightly down from RMB 1,379,970,760.49 at the end of 2022[16] - The total assets at the end of the reporting period were ¥2,430,140,831.12, showing a slight increase of 0.11% from the previous year[6] - The total assets of the company as of March 31, 2023, were RMB 2,430,140,831.12, a slight increase from RMB 2,427,357,984.04 at the end of 2022[18] - The company's total assets at the end of Q1 2023 were CNY 608,483,017.48, a decrease from CNY 658,439,367.69 at the end of Q1 2022[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,636[13] - The top shareholder, Wuhu Lian Tai Investment Management Center, holds 180,509,529 shares, accounting for 10.06% of the total shares[13] - The company repurchased a total of 19,381,400 shares, representing 1.08% of the total share capital[14] Expenses and Liabilities - Total operating costs for Q1 2023 were RMB 427,154,766.87, up from RMB 396,082,288.84 in Q1 2022, reflecting a year-over-year increase of 7.1%[20] - Research and development expenses increased to CNY 3,183,767.55, a rise of 63.3% from CNY 1,948,187.29 in Q1 2022[21] - Sales expenses rose to CNY 24,101,922.87, an increase of 42.0% compared to CNY 16,996,675.14 in the previous year[21] - The total liabilities decreased to RMB 1,241,086,639.18 from RMB 1,249,813,207.06, showing a reduction of 0.7%[18] - The company incurred a financial expense of CNY -3,485,466.02, an improvement from CNY -4,746,494.28 in Q1 2022[21] Other Financial Metrics - The weighted average return on equity increased by 0.44 percentage points to 1.48%[6] - The prepayments increased significantly by 46.84%, indicating higher procurement activity during the period[10] - The company reported a government subsidy of ¥310,500 related to its normal business operations[8] - Accounts receivable increased to RMB 109,041,067.70 from RMB 102,852,835.07, indicating a rise of 6.4%[16] - Inventory levels rose to RMB 84,402,350.18, compared to RMB 74,211,106.40 at the end of 2022, marking a 13.7% increase[16] - The company's equity attributable to shareholders increased to RMB 1,422,934,095.59 from RMB 1,412,474,673.65, reflecting a growth of 0.7%[18] - The company reported a net loss of RMB 1,487,820,903.82, slightly improved from a loss of RMB 1,508,808,057.98 in the previous period[18]